Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

ClinicalTrials.gov ID: NCT05620836

Public ClinicalTrials.gov record NCT05620836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.

Study identification

NCT ID
NCT05620836
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
619 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2023
Primary completion
Jan 6, 2025
Completion
Nov 20, 2025
Last update posted
Jan 8, 2026

2023 – 2025

United States locations

U.S. sites
38
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Investigative Site US240 Scottsdale Arizona 85255
Investigative Site US237 Scottsdale Arizona 85259
Investigative Site US214 Arkansas City Arkansas 72758
Investigative Site US242 Fayetteville Arkansas 72703
Investigative Site US223 Los Angeles California 90033
Investigative Site US226 San Diego California 92103
Investigative Site US222 San Francisco California 94118
Investigative Site US233 Washington D.C. District of Columbia 20060
Investigative Site US228 Brandon Florida 33511
Investigative Site US227 Margate Florida 33063
Investigative Site US204 Miami Florida 33125
Investigative Site US236 Miami Florida 33173
Investigative Site US200 Ocala Florida 34470
Investigative Site US201 Tampa Florida 33613
Investigative Site US220 West Dundee Illinois 60118
Investigative Site US206 Indianapolis Indiana 46250
Investigative Site US241 Iowa City Iowa 52242
Investigative Site US209 Louisville Kentucky 40241
Investigative Site US207 Metairie Louisiana 70006
Investigative Site US229 New Orleans Louisiana 70115
Investigative Site US224 Baltimore Maryland 21224
Investigative Site US208 Beverly Massachusetts 01915
Investigative Site US221 Quincy Massachusetts 02169
Investigative Site US213 Detroit Michigan 48084
Investigative Site US217 Waterford Michigan 48328
Investigative Site US212 Minneapolis Minnesota 55455
Investigative Site US239 Omaha Nebraska 68144
Investigative Site US230 Hightstown New Jersey 08520
Investigative Site US202 New York New York 10003
Investigative Site US210 Rochester New York 14642
Investigative Site US205 Chapel Hill North Carolina 27516
Investigative Site US215 Bexley Ohio 43209
Investigative Site US203 Columbus Ohio 43210
Investigative Site US232 Murfreesboro Tennessee 37130
Investigative Site US235 Arlington Texas 76011
Investigative Site US218 Bellaire Texas 77401
Investigative Site US238 Pflugerville Texas 78660
Investigative Site US234 San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05620836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05620836 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →